Quantitative Assessment the Longitudinal Changes of Pulmonary Vascular Counts in Chronic Obstructive Pulmonary Disease

Sang Won Park

Kangwon National University <https://orcid.org/0000-0001-9796-2799>

Myoung-Nam Lim

Kangwon National University Hospital

Woo Jin Kim

Kangwon National University Hospital

So Hyeon Bak (✉ arsgnm17@gmail.com)

Kangwon National University, Chuncheon, Republic of Korea <https://orcid.org/0000-0003-1039-7016>

Research

Keywords: Chronic Obstructive Pulmonary Disease, Computed Tomography, Longitudinal study, Pulmonary Function Tests, Pulmonary vascular

Posted Date: September 7th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-861379/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Respiratory Research on February 14th, 2022. See the published version at <https://doi.org/10.1186/s12931-022-01953-7>.

Abstract

Background

Chest computed tomography(CT) is a widely used method to assess morphological and dynamic abnormalities in chronic obstructive pulmonary disease (COPD). The small pulmonary vascular cross-section (CSA), quantitatively extracted from volumetric CT, is a reliable indicator for predicting pulmonary vascular changes. CSA is associated with the severity of symptoms, pulmonary function tests (PFT) and emphysema and in COPD patients the severity increases over time. However, there are few studies of changes in vascular during longitudinal follow-up in COPD patients. We analyzed the correlation longitudinal changes in pulmonary vascular parameters with clinical parameters in COPD patients.

Materials and Methods

A total of 288 subjects with COPD were investigated during follow up period up to 6 years. CT images were classified into five subtypes from normal to severe emphysema according to percentage of low-attenuation areas less than -950 and -856 Hounsfield units (HU) on inspiratory and expiratory CT (LAA-950, LAA-856^{exp}). Total number of vessels (N_{total}) and total number of vessels with area less than 5 mm² ($N_{<5mm}$) per 1 cm² of lung surface area (LSA) were measured at 6 mm from the pleural surface.

Results

N_{total}/LSA and $N_{<5mm}/LSA$ changed from 1.16 ± 0.27 to 0.87 ± 0.2 and from 1.02 ± 0.22 to 0.78 ± 0.22 , respectively, during Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage progression. Both parameters changed from normal to severe emphysema according to CT subtype from 1.39 ± 0.21 to 0.74 ± 0.17 and from 1.18 ± 0.19 to 0.67 ± 0.15 , respectively. LAA-950 and LAA-856^{exp} were negatively correlated with N_{total}/LSA ($r = -0.738, -0.529$) and $N_{<5mm}/LSA$ ($r = -0.729, -0.497$). On the other hand, pulmonary function test (PFT) results showed a weak correlation with N_{total}/LSA and $N_{<5mm}/LSA$ ($r = 0.205, 0.210$). The depth in CT subtypes for longitudinal change both N_{total}/LSA and $N_{<5mm}/LSA$ was $(-0.032, -0.023)$ and (-0.027) in normal and SAD, respectively.

Conclusions

Quantitative computed tomography features faithfully reflected pulmonary vessel alterations, showing in particular that pulmonary vascular alteration started.

Trial registration

We obtained the written informed consent from all participants in this study and the approval for all processes by our institution Institutional Review Board.

Introduction

Chronic obstructive pulmonary disease (COPD) is a multifaceted disease characterized by airflow obstruction, and is associated with chronic inflammatory response of the airways, often involving destruction of adjacent alveoli and vasculature[1, 2]. COPD have been known as a heterogeneous and complex condition with a variety of pathological and clinical compartments[3, 4]. Pulmonary vascular alteration is a major pathophysiological characteristic of COPD[5]. It is estimated that 30–70% of COPD patients have some degree of pulmonary vascular abnormalities due to pulmonary hypertension[6, 7]. Passive vascular compression by emphysema and hypoxic pulmonary vasoconstriction

are thought to be critical for the pathogenesis of vascular changes, and recent studies have suggested that endothelial dysfunction is associated with vascular alterations in patients with COPD[2, 8, 9].

The gold standard for evaluating pulmonary vascular abnormality and hemodynamics is right heart catheterization, which is too invasive in clinical practice[2]. Angiographic studies of smokers showed narrowing and reduction of small pulmonary arteries in regions severely affected by emphysema[10, 11]. Chest computed tomography (CT) is widely used to evaluate the morphologic and dynamic abnormalities of COPD. The cross-sectional areas (CSAs) of the small pulmonary vessels, quantitatively extracted from volumetric CT, are reliable indicators of pulmonary vascular alteration[9]. CSAs are associated with symptoms, pulmonary function test (PFT), and severity of emphysema[5, 8, 9]. The extent of emphysema increases over time in patients with COPD[12]. However, there are few studies on the changes in vascular alterations during longitudinal follow-up in patients with COPD.

In this study, we conducted a quantitative analysis based on volumetric CT scans to identify vessel alterations in patients with COPD. The purpose of our study was to determine the differences in pulmonary vascular parameters measured by volumetric CT according to disease severity and CT phenotype, and to assess their correlations with clinical parameters. In addition, we observed longitudinal vascular changes in the subjects, classified by Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade and CT subtype, during a follow-up period of up to 6 years.

Methods

Subjects

A total 504 of subjects were collected from the COPD in Dusty Areas (CODA) cohort, which consisted of Korean subjects residing near cement plants. As a prospective study, all subjects underwent medical interviews, PFTs, laboratory tests, and chest CT. COPD was diagnosed in subjects with post-bronchodilator forced expiratory volume in 1s (FEV₁) / forced vital capacity (FVC) ratio < 0.7 at baseline[13]. We excluded 206 subjects due to FEV₁/FVC ratio $\geq$ 0.7 (n = 162), lung surgery (n = 4), CT quantification error (n = 10), and severe lung parenchymal distortion (n = 30). Thus 288 subjects with COPD were finally investigated in the current study, of which 147 were investigated at least two chest CT scans within 3 years from baseline and 88 were followed up with CT scans at least two for up to 6 years (Fig. 1). Institutional Review Board approval for all processes of this study was obtained from (2012-06-007), and written informed consent was obtained from all subjects.

Clinical and pulmonary function parameters

All subject data were obtained from interviews and assessments of physical condition using questionnaires, including demographic data, medical history, exposure environment, and respiratory symptoms. Dyspnea assessment was conducted using the modified Medical Research Council (mMRC) scale, and quality of life related to health was assessed by calculating the sum of scores on the subject-reported COPD Assessment Test (CAT).

PFTs were performed using the Easy One Kit (NDD, Zurich, Switzerland), before and after inhalation of 400 μ g salbutamol. Specifically, the airflow limitation on spirometry for the severity of COPD is defined using the FEV₁ and the FEV₁/FVC ratio, and divided into four GOLD grades: grade 1 ($\geq$ 80%), grade 2 (50–79%), grade 3 (30–49%), or grade 4 (< 30%)[13]. The number of subjects in grades 3 and 4 was insufficient compared to that of early stage patients, thus grades 3 and 4 were combined into one group.

Chest CT acquisition

All volumetric CT scan images were obtained at full inspiration and expiration in the supine position. Intravenous contrast medium administration was not required. The CT scanners used in this study are first-generation dual-source CT scanners manufactured by Siemens Healthcare (Somatom Definition; Forchheim, Germany) with the following parameters: 140 kVp, 100 mA, beam pitch 0.9-1, slice thickness 0.6 and 3 mm. All acquired CT images were reconstructed using the soft convolution kernel B30f.

Quantitative analysis of CT images

Lung segmentation and quantification of emphysema, air trapping, and pulmonary vessels were performed using an Aview® system (Coreline Soft Inc., Seoul, South Korea). The extent of emphysematous lung was measured by quantifying the fraction of low-attenuation areas less than -950 Hounsfield units (HU) on inspiratory CT scan (LAA-950) (Fig. 2). Air trapping was used to assess the percentage of low attenuation less than or equal to -856 HU measured on expiratory CT scan (LAA-856exp)[14]. CT images were classified into five subtypes according to LAA-950 and LAA-856exp: normal (LAA-950 < 5% and LAA-856exp < 20%), small airway disease (SAD, LAA-950 < 5% and LAA-856exp ≥ 20%), mild emphysema (LAA-950 ≥ 5% and < 10%), moderate emphysema (LAA-950 ≥ 10% and < 15%), and severe emphysema (LAA-950 ≥ 15%)[15].

The methodology for pulmonary vessel quantification is described in detail elsewhere[16]. Pulmonary vessels were extracted using a threshold of -750 HU. The extracted initial vessels were refined in detail as twigs of lung vascular structures using region growing and weighted minimum spanning tree (MST) algorithms with an orientation vector field. After pulmonary vascular structure reconstruction, the lung surface area (LSA) at a depth of 6 mm from the pleural surface was computed[17]. For each surface area, the total number of vessels (N_{total}) and total number of vessels with vessel area less than 5 mm² ($N_{<5\text{mm}}$) were counted as robust values, and reported as values per 1 cm² of LSA ($N_{\text{total}}/\text{LSA}$; $N_{<5\text{mm}}/\text{LSA}$).

Statistical analysis

Continuous variables were expressed as mean ± standard deviation. Differences between two groups were evaluated using independent sample t-tests and the chi-square statistics. One-way ANOVA was used to analyze the differences between the measured quantitative and qualitative pulmonary vessel changes and parameters. A mixed model was used to longitudinally analyze the changes in time of qualitatively and quantitatively measured pulmonary vessel parameters during the follow-up period of up to 6 years. Pearson's correlation analysis was used to measure the associations between pulmonary vessel parameters and clinical parameters such as FEV₁, FEV₁/FVC, CAT, LAA-950, and LAA-856exp. For all statistical analyses, p-values < 0.05 were considered statistically significant. All statistical analyses were performed using SAS (Version 9.4, SAS Institute, Cary, NC) and R (Version 3.6.3, The R Foundation for 211 Statistical Computing, Vienna, Austria; 64-bit platform).

Results

Patient characteristics

Table 1 presents the demographic characteristics of the study cohort. The 288 subjects included 236 (81.9 %) men and 52 (18.1 %) women. The mean age was 72.88 ± 7.27 (range 44.0 to 96.0) years. Regarding smoking history, the subjects included 71 non-smokers, 138 former smokers, and 76 current smokers, with mean pack-years 21.03 ± 25.49. The mean body mass index (BMI) of the subjects was 23.17 ± 3.13 kg/m², the mMRC score 1.48 ± 1.16, and the CAT score 17.06 ± 9.68. The mean pulmonary function evaluation result (FEV₁/FVC) was 58.80 ± 8.64.

Table 1

The characteristics of subjects with COPD in the CODA cohort at baseline.

Characteristics	Total (n = 288)
Gender¹	
Male	236 (81.9)
Female	52 (18.1)
Age²	72.88 ± 7.27
Smoking (n=285)¹	
None(Never)	71 (24.9)
Former	138 (48.4)
Current	76 (26.7)
Pack-years²	21.03 ± 25.49
BMI (kg/m²)²	23.17 ± 3.13
mMRC (n=284)²	1.48 ± 1.16
CAT score (n=284)²	17.06 ± 9.68
GOLD grade¹	
1	147 (51.0)
2	118 (41.0)
3 and 4	23 (8.0)
Pulmonary function Evaluation²	
FVC(%)	3.1 ± 0.8
FEV1(%)	1.8 ± 0.6
FEV1/FVC	58.8 ± 8.6
¹ Indicated data are number and percentages in parentheses. ² Data are mean ± standard deviation (SD). There were 4 non-responders in all patients for mMRC and CAT scores, respectively. Abbreviations: BMI; body mass index, mMRC; modified Medical Research Council, H.U; Hounsfield unit, GOLD; Global Initiative for Chronic Obstructive Lung Disease, CAT; chronic obstructive pulmonary disease assessment test, FEV1; forced expiratory volume in 1 s, FVC; forced vital capacity,	

Vessel quantification according to subtypes

Pulmonary vascular parameters were assessed according to the GOLD grade of the subjects (Table 2). The measured $N_{\text{total}}/\text{LSA}$ and $N_{<5\text{mm}}/\text{LSA}$ decreased as the GOLD grade increased. $N_{\text{total}}/\text{LSA}$ was 1.16 ± 0.27 in GOLD 1, and

decreased to 1.12 ± 0.29 and 0.87 ± 0.27 for GOLD 2 and 3/4, respectively. $N_{<5\text{mm}}/\text{LSA}$ was 1.02 ± 0.22 , 0.99 ± 0.23 and 0.78 ± 0.22 for GOLD 1, 2 and 3/4, respectively, thus more decreased than $N_{\text{total}}/\text{LSA}$. The decrease of $N_{\text{total}}/\text{LSA}$ and that of $N_{<5\text{mm}}/\text{LSA}$ were statistically significant (both $p < 0.001$).

Table 2
Vessel quantification based on GOLD severity criteria

	GOLD1 (n = 147)	GOLD2 (n = 118)	GOLD3,4 (n = 23)	p-value
$N_{\text{total}}/\text{LSA}$	1.16 ± 0.27	1.12 ± 0.29	0.87 ± 0.27	< 0.001
$N_{<5\text{mm}}/\text{LSA}$	1.02 ± 0.22	0.99 ± 0.23	0.78 ± 0.22	< 0.001
Abbreviations: GOLD; Global Initiative for Chronic Obstructive Lung Disease, N_{total} ; Total number of vessels, $N_{<5\text{mm}}$; Total number of vessels with vessel area less than 5 mm^2 , LSA; Lung surface area at 6 mm from the pleural surface.				

In addition, we measured pulmonary vascular parameters according to CT subtype (Table 3). The measured $N_{\text{total}}/\text{LSA}$ and $N_{<5\text{mm}}/\text{LSA}$ were 1.39 ± 0.21 and 1.18 ± 0.19 , respectively, in the normal CT subtype. Both $N_{\text{total}}/\text{LSA}$ and $N_{<5\text{mm}}/\text{LSA}$ decreased to 1.28 ± 0.17 and 1.12 ± 0.14 , respectively, in the SAD subtype, and to 1.05 ± 0.19 and 0.95 ± 0.16 in the mild emphysema subtype. In the moderate and severe emphysema subtypes $N_{\text{total}}/\text{LSA}$ was 0.90 ± 0.18 and 0.74 ± 0.17 , respectively, while $N_{<5\text{mm}}/\text{LSA}$ was 0.82 ± 0.15 and 0.67 ± 0.15 , showing more decreased numbers than $N_{\text{total}}/\text{LSA}$ for increasing emphysema severity. The decrease of both pulmonary vascular parameters was statistically significant (both $p < 0.001$).

Table 3
Vessel quantification based on CT subtypes

	Normal (n = 54)	SAD (n = 88)	Mild (n = 69)	Moderate (n = 34)	Severe (n = 43)	p-value
$N_{\text{total}}/\text{LSA}$	1.39 ± 0.21	1.28 ± 0.17	1.05 ± 0.19	0.90 ± 0.18	0.74 ± 0.17	< 0.001
$N_{<5\text{mm}}/\text{LSA}$	1.18 ± 0.19	1.12 ± 0.14	0.95 ± 0.16	0.82 ± 0.15	0.67 ± 0.15	< 0.001
Abbreviations: N_{total} ; Total number of vessels, $N_{<5\text{mm}}$; Total number of vessels with vessel area less than 5 mm^2 , LSA; Lung surface area at 6 mm from the pleural surface; SAD; Small airway disease.						

Correlation between vessel parameters and clinical/quantitative CT parameters

We also investigated the correlation between the pulmonary vascular parameters and clinical/CT quantitative parameters (Table 4). FEV_1 showed weak but significant positive correlation with $N_{\text{total}}/\text{LSA}$ and $N_{<5\text{mm}}/\text{LSA}$ (correlation coefficient 0.205 and 0.210, respectively, both $p < 0.001$), and FEV_1/FVC had a positive correlation with the same parameters (0.332 and 0.337 with $N_{\text{total}}/\text{LSA}$ and $N_{<5\text{mm}}/\text{LSA}$, respectively, both $p < 0.001$).

LAA-950 and LAA-856exp showed strong negative correlation with $N_{\text{total}}/\text{LSA}$ and $N_{<5\text{mm}}/\text{LSA}$ (LAA-950: correlation coefficients – 0.738 and – 0.729 with $N_{\text{total}}/\text{LSA}$ and $N_{<5\text{mm}}/\text{LSA}$, respectively; LAA-856^{exp}: -0.529 and – 0.497, $p < 0.001$). However, pulmonary vascular parameters had no statistically significant correlations with FVC and CAT scores.

Table 4
Correlation between vessel parameters and clinical/quantitative CT parameters

	Post FEV ₁ (%)	Post FEV ₁ /FVC	Post FVC	CAT	LAA-950	LAA-856exp
$N_{\text{total}}/\text{LSA}$	0.21 ¹	0.33 ¹	0.07	-0.04	-0.74 ¹	-0.53 ¹
$N_{<5\text{mm}}/\text{LSA}$	0.21 ¹	0.34 ¹	0.08	-0.08	-0.73 ¹	-0.50 ¹
¹ $p < 0.001$						
Abbreviations: N_{total} ; Total number of vessels, $N_{<5\text{mm}}$; Total number of vessels with vessel area less than 5 mm ² , LSA; Lung surface area at 6 mm from the pleural surface; FEV ₁ ; Forced expiratory volume in 1s; FVC; Forced vital capacity; CAT; COPD Assessment Test; LAA-950; Low-attenuation areas less than – 950 Hounsfield unit on inspiration; LAA-856; Low-attenuation areas less than – 856 Hounsfield unit on expiration.						

Longitudinal changes over a follow up period

We analyzed the pattern of pulmonary vascular parameter changes during the entire follow-up period of up to 6 years from baseline (Table 5). Changes over time were observed according to CT subtypes and GOLD grades (Fig. 3). The longitudinal analysis of pulmonary vascular parameters showed a tendency for $N_{<5\text{mm}}/\text{LSA}$ to decrease during the follow-up period as the severity increased from GOLD 1 to GOLD 3/4. However, the same pattern of change was not observed for $N_{\text{total}}/\text{LSA}$, and neither vascular parameter showed a statistically significant change pattern.

Unlike GOLD grades, CT subtypes based on volumetric quantitative analysis results of emphysema and air trapping severity would clearly indicate a decline. The CT image-based quantitative volumetric scan results reflect the longitudinal changes over a follow-up period of up to 6 years of the $N_{\text{total}}/\text{LSA}$ and $N_{<5\text{mm}}/\text{LSA}$ from the normal to the severe stage (Additional file 1, Tables 1,2). Both pulmonary vascular parameters exhibited a more pronounced decrease from normal to mild, than from moderate to severe. The results of depth of longitudinal change in $N_{\text{total}}/\text{LSA}$ progressed – 0.032 and – 0.023 in normal and SAD, respectively. In addition, the change in $N_{<5\text{mm}}/\text{LSA}$ was – 0.027 and – 0.027 in the same subtypes. Moreover, only $N_{\text{total}}/\text{LSA}$ showed a statistically significant result (p value of 0.031) over the entire follow-up period.

Table 5
Longitudinal changes over a follow up period up to 6 years

	GOLD severity				CT subtype					
	1	2	3,4	p	Normal	SAD	Mild	Moderate	Severe	p
N _{total} /LSA	-0.014 (-0.025, -0.004)	-0.007 (-0.024, 0.009)	-0.016 (-0.038, 0.006)	0.61	-0.032 (-0.054, -0.011)	-0.023 (-0.037, -0.008)	-0.005 (-0.022, 0.013)	0.013 (-0.021, 0.047)	-0.003 (-0.021, 0.015)	0.03
N _{<5mm} /LSA	-0.019 (-0.026, -0.012)	-0.014 (-0.020, -0.007)	-0.006 (-0.019, 0.008)	0.30	-0.027 (-0.041, -0.013)	-0.027 (-0.034, -0.019)	-0.008 (-0.014, -0.001)	0.001 (-0.015, 0.017)	-0.005 (-0.016, 0.005)	0.40
Abbreviations: GOLD; Global Initiative for Chronic Obstructive Lung Disease; N _{total} ; Total number of vessels; N _{<5mm} ; Total number of vessels with vessel area less than 5 mm ² ; LSA; Lung surface area at 6 mm from the pleural surface; SAD; Small airway disease.										

Discussion

In this study, we performed a quantitative analysis of pulmonary vessel changes according to GOLD grade and CT subtype. As the GOLD grade based on PFT and the emphysema severity based on volumetric chest CT increased, the number of pulmonary vessels consistently decreased. In addition, quantitative longitudinal analysis up to 6 years demonstrated that the number of vessels decreased more significantly in the normal and SAD subtypes than in the emphysema subtypes, while no significant differences were observed according to GOLD grades.

Pulmonary vascular alteration is an important complication in the natural history of COPD, but its pathophysiologic mechanisms are still poorly understood[18]. Endothelial dysfunction is a major cause of vascular remodeling and emphysema[2, 8, 19]. Chest CT could quantitatively assess macroscopic pulmonary vascular alterations in subjects with COPD. The ratio of the main pulmonary artery to the ascending aorta diameter has been suggested as an important marker for pulmonary vascular disease[18]. Approximately 66 % of subjects with COPD have some degree of pulmonary hypertension, and a pulmonary artery-to-ascending-aorta ratio > 1 was associated with acute exacerbation (AE) and mortality in patients with COPD[20–22]. Our previous study showed that the pulmonary artery-to-ascending aorta ratio was correlated with FEV₁ in patients with mild to moderate COPD[23]. In addition, a study using CT and cardiac magnetic resonance imaging reported that pulmonary artery enlargement is associated with the loss of blood volume in the distal pulmonary vessels in patients with COPD[24].

The CSAs of the small pulmonary vessels can be evaluated quantitatively on CT to identify pulmonary vascular alterations in patients with COPD[18, 25]. Several studies found the CSAs of small pulmonary vessels to be associated with symptoms, pulmonary artery pressure, pulmonary function, exercise capacity, AE of COPD, and mortality[5, 26, 27]. In our study, similar to other studies, N_{total}/LSA and N_{<5mm}/LSA showed a distinct decrease as the GOLD grades progressed. Histological studies have shown that a greater degree of emphysema and SAD are associated with pulmonary vascular alteration[28, 29]. Downregulation of lung vascular endothelial growth factor (VEGF) and upregulation of inducible nitric oxide synthase (iNOS), which can lead to endothelial dysfunction, play crucial roles in the development of vascular alteration and emphysema[6, 19, 30]. Previous studies have found a relationship between quantitative CT vascular parameters and emphysema[8, 17]. Likewise, the current study showed that N_{total}/LSA and

$N_{<5mm}/LSA$ were negatively correlated with LAA-950. In addition, the quantitative assessment of pulmonary vascular alterations may be more strongly associated with the extent of emphysema than the PFT results.

COPD is a heterogeneous disease with various clinical and pathologic characteristics, and can traditionally be distinguished into two phenotypes: emphysema and airway disease[31, 32]. VEGF is a potential mediator of pulmonary vascular remodeling, and its expression increases in the airway of bronchitis-type patients, leading to abnormal proliferation of endothelial and vascular smooth muscle cells in pulmonary vessels[33]. A study reported that pulmonary vascular alteration was more strongly associated to the emphysema phenotype than to the bronchitis phenotype in patients with COPD[8]. In our study, the analysis was conducted by dividing the patients into five subtypes based on quantitative CT analysis. Compared with the emphysema phenotype, N_{total}/LSA and $N_{<5mm}/LSA$ were significantly higher in the SAD phenotype. Therefore, the results of our study confirmed that pulmonary vascular alteration was more severe in the emphysema phenotype than in the airway phenotype.

In the past, pulmonary vascular disease was considered an end-stage feature of COPD, and pulmonary hypertension was observed in 90 % of patients with GOLD grade 4 COPD[17, 34]. However, recent studies have shown that pulmonary vascular alteration occurs in the setting of subclinical and early stage COPD by an impairment of endothelial function in pulmonary vessels[4, 18, 25, 35, 36]. Emphysema and air trapping progressed over time in smokers[12]. Some studies reported that emphysema increased over 2–3 years, whereas the CSAs of small pulmonary vessels did not decrease[9, 37]. In our study, there were no changes in each GOLD grade, but the number of vessels decreased in the normal and SAD CT subtype over the follow-up period of up to 6 years. This suggests that vessel changes over time were more prominent in the normal and SAD phenotype than in the emphysema phenotype. However, various factors could have affected this result, because the pulmonary hemodynamics affecting quantitative CSA assessment can be changed by breath-holding, circulating blood volume, and treatment[9, 37, 38].

This study has several limitations. First, we quantitatively measured the pulmonary vessel count change based on volumetric chest CT, but could not distinguish between the pulmonary artery and vein. Second, the gold standard for assessing pulmonary vascular abnormality and pulmonary hypertension is right heart catheterization, but this was not done in our study because of the invasiveness of the method. Third, a longitudinal analysis was performed over the 6-year follow-up period, but the baseline values of the subjects were not uniform. Over the entire observation period, the number of observed subjects gradually decreased, leading to lack of statistical power to detect statistical significance in the longitudinal observation of pulmonary vascular changes. Therefore, validation of our results in a large cohort study is necessary.

List Of Abbreviations

AE

Acute Exacerbation

CAT

COPD Assessment Test.

CODA

COPD in Dusty Area

COPD

Chronic Obstructive Lung Disease

CSAs

Cross-Sectional Areas

CT

Computed Tomography

EI

CT-Emphysema Index

FEV₁

Forced Expiratory Volume in 1s

FVC

Forced Vital Capacity

GOLD

Global Initiative for Obstructive Lung Disease.

HU

Hounsfield Unit

iNOS

inducible Nitric Oxide Synthase (iNOS)

LAA-950

Low-Attenuation Areas less than -950

LSA

Lung Surface Area

mMRC

modified Medical Research Council

N_{total}

Total number of vessels as values per 1 cm²

N_{<5mm}

Total number of vessels with vessel area less than 5 mm²

PFT

Pulmonary Function Test

VEGF

Lung Vascular Endothelial Growth Factor

Declarations

Ethics approval and consent to participate

The study was approved by Institutional Review Board of Kangwon National University Hospital (KNUH, 2012-06-007). All participants gave their written informed consent. Our study was conducted in accordance with the amended Declaration of Helsinki.

Consent for publication

Consent for publication was obtained from all participants.

Competing interests

The authors have no financial conflicts of interest.

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF 2018R1D1A1B07049670).

Contributions

S.H.B. takes responsibility for the content of the manuscript, including the data and analysis. S.H.B. and W.J.K. were responsible for conceptualization; S.H.B. and W.J.K. conducted data collection; S.W.P., M.N.L., and S.H.B. performed data curation; S.W.P., M.N.L., S.H.B. conducted formal analysis; S.H.B. and W.J.K. were responsible for funding acquisition; S.W.P., M.N.L., and S.H.P. performed investigations and methodology; S.W.P., S.H.B. were responsible for project administration; S.H.B. and W.J.K. supervised the study; and S.W.P., and S.H.B. wrote the original draft. All authors contributed to writing, reviewing, and editing of the manuscript.

References

1. Stringer WW, Porszasz J, Bhatt SP, McCormack MC, Make BJ, Casaburi R. Physiologic Insights from the COPD Genetic Epidemiology Study. *J COPD F* 2019;6:256–6
2. Kovacs G, Agusti A, Barberà JA, Celli B, Criner G, Humbert M, et al. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype? *Am J Respir Crit Care Med* 2018;198:1000–11
3. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004;23:932–46
4. Barberà JA, Riverola A, Roca J, Ramirez J, Wagner PD, Ros D, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*

5. Yang T, Chen C, Chen Z. The CT pulmonary vascular parameters and disease severity in COPD patients on acute exacerbation: a correlation analysis. *BMC Pulmonary Medicine* 2021;21:34
6. Estépar RSJ, Kinney GL, Black-Shinn JL, Bowler RP, Kindlmann GL, Ross JC, et al. Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications. *Am J Respir Crit Care Med* 2013;188:231–39
7. Labaki WW, Martinez CH, Martinez FJ, Galbán CJ, Ross BD, Washko GR, et al. The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2017;196:1372–79
8. Matsuoka S, Washko GR, Dransfield MT, Yamashiro T, San Jose Estepar R, Diaz A, et al. Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations with emphysema and airflow limitation. *Acad Radiol* 2010;17:93–99
9. Saruya S, Matsuoka S, Yamashiro T, Matsushita S, Fujikawa A, Yagihashi K, et al. Quantitative CT measurements of small pulmonary vessels in chronic obstructive pulmonary disease: do they change on follow-up scans? *Clinical Physiology and Functional Imaging* 2016;36:211–17
10. Scarrow GD. The pulmonary angiogram in chronic bronchitis and emphysema. *Proc R Soc Med* 1965;58:684–87
11. Cordasco EM, Beerel FR, Vance JW, Wende RW, Toffolo RR. Newer aspects of the pulmonary vasculature in chronic lung disease. A comparative study. *Angiology* 1968;19:399–07
12. Pompe E, Strand M, van Rikxoort EM, Hoffman EA, Barr RG, Charbonnier JP, et al. Five-year Progression of Emphysema and Air Trapping at CT in Smokers with and Those without Chronic Obstructive Pulmonary Disease: Results from the COPDGene Study. *Radiology* 2020;295:218–26
13. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. *Eur Respir J* 2017;49
14. Bhatt SP, Washko GR, Hoffman EA, Newell JD, Bodduluri S, Diaz AA, et al. Imaging Advances in Chronic Obstructive Pulmonary Disease. Insights from the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) Study. *Am J Respir Crit Care Med* 2019;199:286–301
15. Park J, Hobbs BD, Crapo JD, Make BJ, Regan EA, Humphries S, et al. Subtyping COPD by Using Visual and Quantitative CT Imaging Features. *Chest* 2020;157:47–60
16. Park S, Lee SM, Kim N, Seo JB, Shin H. Automatic reconstruction of the arterial and venous trees on volumetric chest CT. *Med Phys* 2013;40:071906
17. Cho YH, Lee SM, Seo JB, Kim N, Bae JP, Lee JS, et al. Quantitative assessment of pulmonary vascular alterations in chronic obstructive lung disease: Associations with pulmonary function test and survival in the KOLD cohort. *Eur J Radiol* 2018;108:276–82
18. Blanco I, Tura-Ceide O, Peinado VI, Barberà JA. Updated Perspectives on Pulmonary Hypertension in COPD. *Int J Chron Obstruct Pulmon Dis* 2020;15:1315–24
19. Kasahara Y, Tudor RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. *Am J Respir Crit Care Med* 2001;163:737–44
20. Aluja Jaramillo F, Gutierrez FR, Díaz Telli FG, Yevenes Aravena S, Javidan-Nejad C, Bhalla S. Approach to Pulmonary Hypertension: From CT to Clinical Diagnosis. *Radiographics* 2018;38:357–73

21. Shin S, King CS, Brown AW, Albano MC, Atkins M, Sheridan MJ, et al. Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. *Respiratory Medicine* 2014;108:1626–32
22. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, et al. Pulmonary Arterial Enlargement and Acute Exacerbations of COPD. *New England Journal of Medicine* 2012;367:913–21
23. Hahm CR, Lim MN, Kim HY, Hong S-H, Han S-S, Lee S-J, et al. Implications of the pulmonary artery to ascending aortic ratio in patients with relatively mild chronic obstructive pulmonary disease. *J Thorac Dis* 2016;8:1524–31
24. Wells J. Michael, Iyer Anand S., Rahaghi Farbod N., Bhatt Surya P., Gupta Himanshu, Denney Thomas S., et al. Pulmonary Artery Enlargement Is Associated With Right Ventricular Dysfunction and Loss of Blood Volume in Small Pulmonary Vessels in Chronic Obstructive Pulmonary Disease. *Circulation: Cardiovascular Imaging* 2015;8:e002546
25. Uejima I, Matsuoka S, Yamashiro T, Yagihashi K, Kurihara Y, Nakajima Y. Quantitative computed tomographic measurement of a cross-sectional area of a small pulmonary vessel in nonsmokers without airflow limitation. *Jpn J Radiol* 2011;29:251–55
26. Yoshimura K, Suzuki Y, Uto T, Sato J, Imokawa S, Suda T. Morphological changes in small pulmonary vessels are associated with severe acute exacerbation in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2016;11:1435–45
27. Washko GR, Nardelli P, Ash SY, Vegas Sanchez-Ferrero G, Rahaghi FN, Come CE, et al. Arterial Vascular Pruning, Right Ventricular Size, and Clinical Outcomes in Chronic Obstructive Pulmonary Disease. A Longitudinal Observational Study. *Am J Respir Crit Care Med* 2019;200:454–61
28. Wright JL, Lawson L, Paré PD, Hooper RO, Peretz DI, Nelems JM, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise. *Am Rev Respir Dis* 1983;128:702–7
29. Hale KA, Niewoehner DE, Cosio MG. Morphologic changes in the muscular pulmonary arteries: relationship to cigarette smoking, airway disease, and emphysema. *Am Rev Respir Dis* 1980;122:273–78
30. Weissmann N. Chronic Obstructive Pulmonary Disease and Pulmonary Vascular Disease. A Comorbidity? *Ann Am Thorac Soc* 2018;15:S278–81
31. Filley GF, Beckwitt HJ, Reeves JT, Mitchell RS. Chronic obstructive bronchopulmonary disease. II. Oxygen transport in two clinical types. *Am J Med* 1968;44:26–38
32. Vanfleteren LEGW, Spruit MA, Groenen M, Gaffron S, van Empel VPM, Bruijnzeel PLB, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013;187:728–35
33. Kanazawa H, Asai K, Nomura S. Vascular endothelial growth factor as a non-invasive marker of pulmonary vascular remodeling in patients with bronchitis-type of COPD. *Respiratory Research* 2007;8:22
34. Chaouat A, Bugnet A-S, Kadaoui N, Schott R, Enache I, Ducoloné A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;172:189–94
35. Synn AJ, Li W, San José Estépar R, Zhang C, Washko GR, O'Connor GT, et al. Radiographic pulmonary vessel volume, lung function and airways disease in the Framingham Heart Study. *Eur Respir J* 2019;54
36. Santos S, Peinado VI, Ramírez J, Melgosa T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. *European Respiratory Journal* 2002;19:632–38
37. Takayanagi S, Kawata N, Tada Y, Ikari J, Matsuura Y, Matsuoka S, et al. Longitudinal changes in structural abnormalities using MDCT in COPD: do the CT measurements of airway wall thickness and small pulmonary

38. Matsuura Y, Kawata N, Yanagawa N, Sugiura T, Sakurai Y, Sato M, et al. Quantitative assessment of cross-sectional area of small pulmonary vessels in patients with COPD using inspiratory and expiratory MDCT. *Eur J Radiol* 2013;82:1804–10

Figures

Figure 1

Selection of patients with chronic obstructive pulmonary disease (COPD). Patients who were visited at least once during the 6-year follow-up period were selected. FEV1, forced expiratory volume in 1s; FVC, forced vital capacity.

Figure 2

CT quantification of emphysema and pulmonary vessels. (A) CT coronal reconstructed image of a 54-year-old male with COPD GOLD grade 1 reveals centrilobular and paraseptal emphysema. (B) The emphysema was measured using a threshold of -950HU (shown in green; LAA-950, 12.3%). (C) Pulmonary vessels are automatically extracted and segmented (shown in red; N_{total}/LSA , 1.05; N_{5mm}/LSA , 0.97), and the green contours show the lung surface area at 6 mm from the pleural surface. CT, computed tomography; LAA, low attenuation area.

Figure 3

Longitudinal changes of vessel quantification during up to 6 years by GOLD grade and CT subtype. No significant differences were observed according to GOLD grade. However, the number of vessels during the initial COPD symptom progression (CT subtype normal to SAD) was markedly reduced, although without visually structural changes in the CT image. In other words, the decrease of vessels counts over 6 years was more pronounced in the airway disease phenotype than in the emphysema phenotype. GOLD, Global Initiative for Chronic Obstructive Lung Disease; CT, computed tomography; SAD, small airway disease.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1.docx](#)